Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Short-Course Radiotherapy + CAPOX + Tislelizumab vs Long-Course Chemoradiotherapy + Tislelizumab for LARC
NCT07469306Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab, oxaliplatin and capecitabine in rectal cancer (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Complete Response Rate at 12 months. Started Aug 2026; status: recruiting.
02
Drugs
tislelizumaboxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07469306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469306.